SONY

Product Data Sheet

Brilliant Violet 570™ anti-mouse CD90.2

Catalog # / Size: 1126645 / 125 µl

Clone: 30-H12

Isotype: Rat IgG2b, κ

Immunogen: Mouse thymus or spleen

Reactivity: Mouse

Preparation: The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 570™ under optimal conditions. The solution is free of unconjugated Brilliant Violet 570™ and unconjugated antibody.

Formulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).

Concentration: Lot-specific



C57BL/6 splenocytes were stained with CD90.2 (clone 30-H12) Brilliant Violet 570™ (filled histogram) or rat IgG2b, κ Brilliant Violet 570™ isotype control (open histogram).

Applications:

Applications: Flow Cytometry

Recommended Usage: Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤5 microL per million cells or 5 microL per 100 microL of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.

Brilliant Violet 570™ excites at 405 nm and emits at 570 nm. The bandpass filter 585/42 nm is recommended for detection, although filter optimization may be required depending on other fluorophores used. **Be sure to verify that your cytometer configuration and software setup are appropriate for detecting this channel.** Refer to your instrument manual or manufacturer for support. Brilliant Violet 570™ is a trademark of Sirigen Group Ltd.

This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.

Application Notes: Additional reported applications (for the relevant formats) include: *in vivo* and *in vitro* depletion[1,2,7], costimulation of CD3/TCR-mediated signal transduction[3,4], and immunohistochemical staining5 of acetone-fixed frozen sections. The 30-H12 antibody does not react with Thy-1.1 alloantigen of the AKR/J and PL strains. To reduce non-specific binding to cells bearing Fc-receptors, pre-incubation of cells with anti-mouse CD16/CD32, clone 93 (Cat. No. 101301/101302) is recommended prior to immunofluorescent staining. The LEAF™ purified antibody (Endotoxin <0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 105310).

Application

1. Hathcock KS. 1991. Current Protocols in Immunology. 3.4.1. (Deplete)

References:
2. Seaman WE. 1983. *J. Immunol.* 130:1713. (Deplete)
3. Nakashima I, *et al.* 1991. *J. Immunol.* 147:1153. (Costim)
4. Nakashima I, *et al.* 1993. *J. Immunol.* 151:3511. (Costim)
5. Ledbetter JA, *et al.* 1980. *J. Exp. Med.* 152:280. (IHC)
6. Hardy B, *et al.* 2005. *Int. Immunol.* 17:615.
7. Drobyski W, *et al.* 1996. *Blood* 87:5355. (Deplete)
8. Dyer KD, *et al.* 2007. *J. Immunol.* 179:1693. (FC) PubMed

---

Description: CD90.2 is a 25-35 kD immunoglobulin superfamily member also known as Thy1.2. It is expressed on hematopoietic stem cells and neurons, all thymocytes, and peripheral T cells in Thy1.2 bearing mouse strains (Balb/c, CBA/J, C3H/He, C57BL/-, DBA, NZB/-). CD90.2 is a glycosylphosphatidylinositol (GPI)-anchored membrane glycoprotein involved in signal transduction. CD90.2 is involved in costimulation of lymphocyte proliferation and induction of hematopoietic stem cells differentiation. CD90.2 has been shown to interact with CD45. The 30-H12 antibody has been reported to induce Ca^{2+} flux in thymocytes and, in combination with antibody against the CD3/TCR complex, promote thymocyte apoptosis and inhibit CD3-mediated proliferative responses of mature T lymphocytes.

Antigen References:
1. Barclay A, *et al.* 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Craig W, *et al.* 1993. *J. Exp. Med.* 177:1331.
3. Reif AE and Schlesinger M. 1989. Cell Surface Antigen Thy-1.
4. Mayani H, *et a*